ArticleWorld journal of urology2025

Clinical effectiveness and safety of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): a single-center retrospective study.

Xi Zhong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.